Is Wockhardt a good stock to invest in?

Wockhardt can be analyzed on the following key metrics - TTM P/E: - Sector P/E: 24.5 Dividend Yield: 0% D/E ratio: -

Wockhardt Share Price

Sector: Biotechnology & Drugs

Powered by

1325.00 -34.35 (-2.53%)

1D
5D
1M
3M
6M
1Y
5Y
MAX

Price Range

Today’s Low 1316.05

Today’s High 1372.40

52 Week Low 489.20

52 Week High 1678.60

Key Metrics

Market Cap (In Cr) 21535.59
Beta 1.88
Div. Yield (%) 0
P/B 6.21
TTM P/E -
Peg Ratio -
Sector P/E 24.5
Open Price 1369.95
Prev Close 1359.35

View All Metrics

Wockhardt Analysis

Price Analysis

1 Week

7%
3 Months

-3.64%
6 Month

19.61%
YTD

-4.09%
1 Year

150.1%

Risk Meter

58% Low risk
58% Moderate risk
58% Balanced Risk
58% High risk
58% Extreme risk

Wockhardt News

The UK-India economic corridor has always been one of huge potential and promise.
(Piyush Goyal-X)

Premium

India-UK trade deal: Stay focused on the long-term prize

4 min read . 12 May 2025

Premium

How Wockhardt is packing for the road less travelled

7 min read . 03 Apr 2025

Your brain associates a particular food with a memory. If it's a happy memory, you are inclined to repeat the experience. (Unsplash/Fotos)

Premium

A practical guide to help you cut back on processed foods

5 min read . 09 Mar 2025

Recommended stocks to buy or sell: Raja Venkatraman, co-founder, NeoTrader, recommends three stocks for 21 February.

Premium

Stocks to buy or sell: Raja Venkatraman recommends three stocks for 21 February

4 min read . 21 Feb 2025

View More News

Wockhardt Financials

INCOME
BALANCE SHEET
Cashflow

DATE

Annual

Quarterly

Period
2024

Total Revenue
2798

Selling/ General/ Admin Expenses Total
1170

Depreciation/ Amortization
223

Other Operating Expenses Total
218

Total Operating Expense
2944

Operating Income
-146

Net Income Before Taxes
-420

Net Income
-463

Diluted Normalized EPS
-25.56

Period
2023

Total Revenue
2651

Selling/ General/ Admin Expenses Total
1149

Depreciation/ Amortization
251

Other Operating Expenses Total
225

Total Operating Expense
2972

Operating Income
-321

Net Income Before Taxes
-624

Net Income
-559

Diluted Normalized EPS
-25.35

Period
2022

Total Revenue
3230

Selling/ General/ Admin Expenses Total
1353

Depreciation/ Amortization
247

Other Operating Expenses Total
225

Total Operating Expense
3362

Operating Income
-132

Net Income Before Taxes
-411

Net Income
-244

Diluted Normalized EPS
-10.37

Period
2021

Total Revenue
2708.3

Selling/ General/ Admin Expenses Total
1251.53

Depreciation/ Amortization
246.02

Other Operating Expenses Total
248.68

Total Operating Expense
3157.37

Operating Income
-449.07

Net Income Before Taxes
-568.34

Net Income
686.06

Diluted Normalized EPS
-22.32

Period
2020

Total Revenue
2843.99

Selling/ General/ Admin Expenses Total
1152.7

Depreciation/ Amortization
224.14

Other Operating Expenses Total
265.41

Total Operating Expense
2970.37

Operating Income
-126.38

Net Income Before Taxes
-342.04

Net Income
-69.22

Diluted Normalized EPS
-13.64

Period
2019

Total Revenue
3565.84

Selling/ General/ Admin Expenses Total
1462.74

Depreciation/ Amortization
163.95

Other Operating Expenses Total
340.44

Total Operating Expense
3742.91

Operating Income
-177.07

Net Income Before Taxes
-446.55

Net Income
-194.53

Diluted Normalized EPS
-24.13

View detailed financials

Forecast

Income Sheet (In Cr) Net Income Vs Revenue

Returns Metrics (In Cr) ROA Vs ROE

Forecast

Balance Sheet Asset vs Liability

Forecast

Cash Flow Operating vs Investing

Wockhardt Technical

Moving Average SMA

5 Day1283.78
10 Day1265.85
20 Day1326.42

50 Day1336.69
100 Day1377.01
300 Day1235.64

Wockhardt Peers

Price
Ratio

Name
Latest Price
Change
% Change
52W High
52W Low
Mkt. Cap

J B Chemicals And Pharmaceutical
1704
40.05
2.41
2029
1303
26474.95

Gland Pharma
1498.5
14.35
0.97
2220.95
1200
24688.75

Wockhardt
1325
-34.35
-2.53
1678.6
489.2
21535.59

Eris Lifesciences
1463.05
19.6
1.36
1593
815.5
20043.28

Alembic Pharmaceuticals
970
-58.25
-5.66
1296.15
725.6
19066.62

Wockhardt Shareholding

Shareholding Pattern

*Promoter pledging: 8.95%

Shareholding Trend

Shareholding(%) v/s Date

View All

Corporate Actions

Board Meeting
AGM
Dividends
Bonus
Split
Rights

Meeting Date
Purpose

07-Feb-25
Quarterly Results

13-Nov-24
Quarterly Results

09-Aug-24
Quarterly Results

28-May-24
Audited Results

26-Mar-24
Others

14-Feb-24
Quarterly Results

14-Nov-23
Quarterly Results

14-Aug-23
Quarterly Results

26-May-23
Audited Results & Others

13-Feb-23
Quarterly Results

Meeting Date
Announced on
Purpose

28-Jun-24
06-Jun-24
AGM

14-Aug-23
18-Jul-23
AGM

12-Aug-22
30-May-22
AGM

02-Aug-21
08-Jul-21
AGM

Announced on
Record Date
Ex-Rights Date
Ratio
FV
Premium
Description

06-Jan-22
09-Mar-22
08-Mar-22
3:10
5
220
Rights issue of equity shares of Rs. 5/- each in the ratio of 3:10 @ premium of Rs. 220/-.

View All

Company Profile

ABOUT Wockhardt

Industry Biotechnology & Drugs
ISIN INE049B01025
BSE Code 532300
NSE Code WOCKPHARMA

Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL TABLET, METHYCOBAL INJ, METHYCOBAL D, HAPID, PROXYFEN NANO GEL, LIVATIRA TABLET, LIVATIRA INJ, GABAWOK NT 100, GABAWOK NT 400, ETOBRIX 90, ETOBRIX TH4, ETOBRIX P, GLARZEN CARTRIDGE, GLARZEN DISPOPEN 2, ESOWOK D, TERITIDE, GLIMADAY, SITAWOK, GLARITUS, TRIMETADAY, MOPADAY, INOGLA, and ZINODAP. The Company has manufacturing and research facilities in India, United States of America and the United Kingdom and a manufacturing facility in Ireland.

MANAGEMENT

Habil Fakhruddin Khorakiwala Executive Chairman of the Board
Deepak Madnani Chief Financial Officer
Rashmi Mamtura Compliance Officer, Company Secretary
Murtaza Habil Khorakiwala Managing Director, Executive Director
Huzaifa Habil Khorakiwala Executive Director

WOCKHARDT SUMMARY

Wockhardt is trading 2.53% lower at Rs 1325.00 as compared to its last closing price. Wockhardt has been trading in the price range of 1372.40 & 1316.05. Wockhardt has given -4.09% in this year & 7% in the last 5 days.

The company posted a net profit of 13 Crores in its last quarter.

Listed peers of Wockhardt include J B Chemicals And Pharmaceutical (2.41%), Gland Pharma (0.97%), Wockhardt (-2.53%) etc.

Wockhardt has a 49.09% promoter holding & 50.91% public holding.

FAQs about Wockhardt

Wockhardt is trading at 1325.00 as on 20 May, 2025 3:54:21 PM. This is -2.53% lower as compared to its previous closing price of 1359.35

The market capitalization of Wockhardt is 21535.59 Cr as on 20 May, 2025 3:54:21 PM.

The 52 wk high for Wockhardt is 1678.60 whereas the 52 wk low is 489.20

Wockhardt can be analyzed on the following key metrics -

TTM P/E: -
Sector P/E: 24.5
Dividend Yield: 0%
D/E ratio: -

Wockhardt reported a net profit of -463 Cr in 2024.

Wockhardt Quick Links

Equity Quick Links

Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks

Wockhardt Share Price

Price Range

Price Range

Key Metrics

Wockhardt Analysis

Wockhardt News

India-UK trade deal: Stay focused on the long-term prize

How Wockhardt is packing for the road less travelled

A practical guide to help you cut back on processed foods

Stocks to buy or sell: Raja Venkatraman recommends three stocks for 21 February

Wockhardt Financials

Forecast

Forecast

Forecast

Wockhardt Technical

Wockhardt Peers

Wockhardt Shareholding

Shareholding Pattern

Shareholding Trend

Corporate Actions

Company Profile

ABOUT Wockhardt

MANAGEMENT

WOCKHARDT SUMMARY

FAQs about Wockhardt

Wait for it…

Wait for it…

Congratulations!

Subscribe to continue